Notice of 27th Annual General Meeting along with Integrated Annual Report of the Company for the financial year 2025-26 and Letter for weblink to access Notice and the Integrated Annual Report

Date: August 3, 2026 To, To, The Manager, The Manager Lis�ng Department, Lis�ng Department BSE Limited Na�onal Stock Exchange of India Limited Phiroze Jeejeebhoy Towers Exchange Plaza, 5th floor, Plot no. C/1, Block Dalal Street – Fort Bandra Kurla Complex, Bandra (East), Mumbai 400001 Mumbai 400051 Scrip Code: 544578 N S E S y m b o l : R U B I C O N ISIN- INE506V01022 Sub: No�ce of 27th Annual General Mee�ng along with Integrated Annual Report of the Company for the financial year 2025-26 Dear Sir/Madam, Pursuant to Regula�on 30 and 34 of the Securi�es and Exchange Board of India (Lis�ng Obliga�ons and Disclosure Requirements) Regula�ons, 2015 (“SEBI Lis�ng Regula�ons”), please find enclosed the Integrated Annual Report of the Company for the financial year 2025-26 along with the No�ce convening the 27th Annual General Mee�ng (“27th AGM”) of the Company. In compliance with the applicable Circulars issued by the Ministry of Corporate Affairs ("MCA") and the Securi�es and Exchange Board of India ("SEBI"), the Integrated Annual Report for the Financial Year 2025-26, and the No�ce convening the 27th AGM, are being sent by email to all the eligible members, whose email address is registered with the Company, Registrar to an Issue and Share Transfer Agent or with the Depositories. Addi�onally, copy of leter is enclosed containing a direct web-link for accessing the aforesaid Integrated Annual Report and No�ce of the AGM, to be sent to those members who have not registered their email address. The important informa�on w.r.t the 27th AGM and e-vo�ng is as follows: Sr. No. Par�culars Event Dates 1. Date, Time and Mode Scheduled to be held on Wednesday, August 26, 2026, at 1:00 P.M. (IST) through Video Conferencing (“VC”). 2. Cut-off Date for remote e-vo�ng and Wednesday, August 19, 2026 e-vo�ng at the AGM 3. Commencement of remote e-vo�ng 9:00 A.M. (IST), Saturday, August 22, 2026 4. End of remote e-vo�ng 5.00 P.M. (IST), Tuesday, August 25, 2026 Rubicon Research Limited (formerly known as Rubicon Research Private Limited) | CIN: L73100MH1999PLC119744 Registered Office: Plot No. B-75, MedOne House, Road No. 33, Wagle Estate, Thane West, PIN – 400 604, Maharashtra, India �� +91-22-61414000 / 50414000 | ����� reachus@rubicon.co.in | � www.rubicon.co.in 5. Announcement of Results of remote Within two working days from the conclusion of e-vo�ng together with e-vo�ng done the AGM at the AGM E-vo�ng facility will also be available during the AGM to those members who have not cast their vote through remote e-vo�ng. Other informa�on, including instruc�ons on e-vo�ng and process to atend the AGM, have been provided in the AGM No�ce. The No�ce of the 27th AGM and the Integrated Annual Report for the financial year 2025-26 are also available on the website of the Company at www.rubicon.co.in. Kindly take the above informa�on on record. Thanking you, Yours faithfully, For Rubicon Research Limited (Formerly known as Rubicon Research Private Limited) Deepashree Tanksale Company Secretary and Compliance Officer M. No.: A28132 Encl.: As Above Rubicon Research Limited (formerly known as Rubicon Research Private Limited) | CIN: L73100MH1999PLC119744 Registered Office: Plot No. B-75, MedOne House, Road No. 33, Wagle Estate, Thane West, PIN – 400 604, Maharashtra, India �� +91-22-61414000 / 50414000 | ����� reachus@rubicon.co.in | � www.rubicon.co.in Rubicon Research Limited Integrated Annual Report 2025-26 Corporate Overview Healthcare is meaningful when it reaches people 04-69 with consistency, quality and care they can trust. As expectations evolve, the challenge lies in making 04 About Us therapies more effective, accessible and patient- Scan the QR code to know 06 FY 2025-26 at a Glance more about us centric, without compromising affordability or 07 Global Footprint or outcomes. This is where scientific innovation must 08 Message from our CEO Visit our website move beyond discovery to deliver real impact. www.rubicon.co.in 10 Our Journey 12 Our Manufacturing Capabilities Statutory Reports At Rubicon Research Limited, our journey Our approach is anchored in three defining 14 Our Research is shaped by a clear belief: innovation must principles: Innovation, Quality and Care. 70-160 and Development serve a purpose. As an IP-led specialty Innovation drives us to reimagine drug 15 Our Logistics pharmaceutical company, we bring together delivery and improve better patient and Distribution strong formulation expertise and proprietary outcomes. Quality ensures that every 70 Management drug delivery technologies to solve complex product meets the highest regulatory 16 Our Offerings Discussion and Analysis challenges and improve therapeutic and industry standards. Care remains 18 Our Blueprint for 80 Board’s Report effectiveness. From oral solids to injectables at the heart of everything we do, guiding Scalable Growth and advanced drug-device combinations, our efforts to make healthcare more 101 Business Responsibility 22 Operating Environment and Sustainability Report our diverse portfolio demonstrates a accessible and meaningful for patients Forward-looking statements commitment to addressing unmet medical around the world. 24 Value Creation Model 137 Corporate Some information in this report may needs across global markets. contain forward-looking statements which Governance Report 26 Stakeholder Engagement include statements regarding Company’s expected financial position and results of operations, business plans and prospects 30 Financial Capital etc. and are generally identified by forward-looking words such as “believe,” 34 Manufactured Capital “plan,” “anticipate,” “continue,” “estimate,” “expect,” “may,” “will” or other similar 42 Intellectual Capital words. Forward-looking statements Supported by a strong are dependent on assumptions or basis underlying such statements. We have 48 Human Capital Financial Statements global development chosen these assumptions or basis in good faith, and we believe that they are 58 Natural Capital 161-275 network and robust reasonable in all material respects. However, we caution that actual results, 62 Social and manufacturing performances or achievements could differ materially from those expressed or implied Relationship Capital capabilities, we continue to in such forward-looking statements. We 161 Standalone undertake no obligation to update or revise 66 Board of Directors translate scientific insight any forward-looking statement, whether Financial Statement as a result of new information, future 68 Company Information into real-world solutions. events, or otherwise. 219 Consolidated 69 Historic Financial Financial Statement As we look ahead, our Performance emphasis remains on advancing differentiated therapies, enabling better health outcomes and contributing to a future Contents where healthcare is effective, equitable and within reach for all. Innovation Innovation At Rubicon Research Limited (Rubicon Research), innovation transforms scientific expertise into meaningful healthcare solutions. Our Research & Development capabilities combine deep formulation knowledge with proprietary drug delivery technologies to address complex therapeutic challenges, while our manufacturing excellence ensures these innovations are produced with precision, quality and consistency at scale. This integration ensures that innovation is not confined to discovery, but carried through to delivery, translating into better efficacy, improved patient experience and reliable access. In doing so, science creates holistic value: for patients through better outcomes. Rubicon Research Limited Integrated Annual Report 2025-26 Corporate Overview Statutory Reports Financial Statements About Us Redefining Medicine, Acquisition Elevating Lives Impopharma Canada Limited Validus Pharmaceuticals LLC AimRx 3PL LLC We acquired Impopharma Canada We acquired Validus Pharmaceuticals We acquired AimRx 3PL LLC (AimRx), a Limited, bolstering our capabilities in LLC (Valid [Showing first 8,000 characters — download PDF for full document]